STK11 rs2075604 Polymorphism Is Associated with Metformin Efficacy in Chinese Type 2 Diabetes Mellitus
Table 3
Comparison of clinical characteristics between the responders and nonresponders before and after metformin treatment.
Parameters
Nonresponses
()
Responses
()
Gender
Male
20
34
0.482
Female
12
28
Age (years)
53.20 ± 10.50
52.61 ± 14.92
0.829
BMI (kg/m2)
Baseline
24.27 ± 2.16
23.92 ± 1.74
0.391
After metformin
24.10 ± 4.02
23.32 ± 2.94
0.287
Mean change
−0.17 ± 4.39
−0.59 ± 2.96
0.581
Metformin dosage (mg/d)
Baseline
1479.69 ± 278.78
1479.84 ± 171.172
0.997
Adjusted
1412.50 ± 235.89
1463.71 ± 375.61
0.484
Mean change
−67.19 ± 338.54
−16.13 ± 361.78
0.509
HbA1c (%)
Baseline
6.33 ± 0.92
7.99 ± 1.57
0.000
After metformin
6.05 ± 0.69
5.18 ± 0.85
0.000
Mean change
−0.28 ± 0.74
−2.81 ± 1.57
0.000
FBG (mmol/L)
Baseline
6.44 ± 2.83
8.35 ± 1.88
0.000
After metformin
5.80 ± 1.24
5.60 ± 1.10
0.462
Mean change
−0.83 ± 2.69
−2.83 ± 1.94
0.000
PBG (mmol/L)
Baseline
10.84 ± 5.04
15.60 ± 10.79
0.020
After metformin
9.05 ± 1.85
8.99 ± 1.63
0.878
Mean change
−2.07 ± 5.11
−6.76 ± 10.98
0.025
Data was analyzed by two-sample t-test. BMI: body mass index; HbA1c: glycosylated haemoglobin; FBG: fasting blood glucose; PBG: postprandial blood glucose. The numbers in bold indicated statistically significant values.
